{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:50:09Z","timestamp":1793137809482,"version":"4.5.0"},"reference-count":24,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurology International"],"abstract":"<jats:p>Background: Pediatric optic neuritis (ON) is a rare but severe condition characterized by acute visual impairment, with 3\u20135% of relapsing cases lacking identifiable markers for associated conditions, such as neuromyelitis optica spectrum disorder (NMOSD) or multiple sclerosis (MS); these cases are thus classified as relapsing idiopathic optic neuritis (RION). Corticosteroids are typically used for acute management; however, their prolonged use in children poses significant risks, including central obesity, hypertension, and growth impairment, underscoring the need for nonsteroidal, long-term treatment options. Current strategies for preventing recurrence in pediatric RION are limited due to a lack of data on immunosuppressive efficacy and safety. Given its rarity and the challenges of long-term immunosuppression in children, identifying optimal therapeutic approaches remains critical. Case Presentation: We report a case of a six-year-old girl with RION, who was initially treated with intravenous methylprednisolone (IVMP) and prednisolone (PSL) tapering, and who experienced recurrence eight months post-treatment. Additional corticosteroids and intravenous immunoglobulin (IVIg) were administered during relapse, but, due to adverse effects, treatment was transitioned to mycophenolate mofetil (MMF), enabling early PSL tapering. Conclusions: With MMF, the patient maintained stable vision and achieved a five-year recurrence-free period without notable side effects. In conclusion, this case suggests MMF\u2019s efficacy as a long-term management option for pediatric RION, potentially reducing corticosteroid-related risks.<\/jats:p>","DOI":"10.3390\/neurolint17030044","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T04:34:43Z","timestamp":1742272483000},"page":"44","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Successful Long-Term Treatment of Pediatric Relapsing Idiopathic Optic Neuritis with Mycophenolate Mofetil"],"prefix":"10.3390","volume":"17","author":[{"given":"Shuhei","family":"Fujino","sequence":"first","affiliation":[{"name":"Department of Neurology, Tokyo Metropolitan Children\u2019s Medical Center, Tokyo 183-8561, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Akamine","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Tokyo Metropolitan Children\u2019s Medical Center, Tokyo 183-8561, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichiro","family":"Noda","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Tokyo Metropolitan Children\u2019s Medical Center, Tokyo 183-8561, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahoko","family":"Miyama","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tokyo Metropolitan Children\u2019s Medical Center, Tokyo 183-8561, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11910-020-1024-x","article-title":"Update on Pediatric Optic Neuritis","volume":"20","author":"Gise","year":"2020","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1212\/01.wnl.0000339482.84392.bd","article-title":"Incidence of acquired demyelination of the CNS in Canadian children","volume":"72","author":"Banwell","year":"2009","journal-title":"Neurology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1136\/adc.2009.175422","article-title":"Childhood optic neuritis clinical features and outcome","volume":"96","author":"Absoud","year":"2011","journal-title":"Arch. Dis. Child."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1212\/WNL.0000000000002822","article-title":"Pediatric optic neuritis","volume":"87","author":"Yeh","year":"2016","journal-title":"Neurology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(13)70259-X","article-title":"Optic neuritis","volume":"13","author":"Toosy","year":"2014","journal-title":"Lancet Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11940-011-0159-0","article-title":"Treatment of pediatric optic neuritis","volume":"14","author":"Bonhomme","year":"2012","journal-title":"Curr. Treat. Options Neurol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1097\/WNO.0000000000000551","article-title":"Pediatric Optic Neuritis: What Is New","volume":"37","author":"Borchert","year":"2017","journal-title":"J. Neuroophthalmol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1212\/WNL.49.5.1413","article-title":"Risk factors for developing multiple sclerosis after childhood optic neuritis","volume":"49","author":"Lucchinetti","year":"1997","journal-title":"Neurology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1177\/1352458513510223","article-title":"Relapsing optic neuritis: A multicentre study of 62 patients","volume":"20","author":"Benoilid","year":"2014","journal-title":"Mult. Scler."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199202273260901","article-title":"A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group","volume":"326","author":"Beck","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s11940-010-0071-z","article-title":"Neuromyelitis optica","volume":"12","author":"Carroll","year":"2010","journal-title":"Curr. Treat. Options Neurol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejpn.2020.10.005","article-title":"E.U. paediatric MOG consortium consensus: Part 5\u2014Treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders","volume":"29","author":"Bruijstens","year":"2020","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00415-013-6957-4","article-title":"Chronic relapsing inflammatory optic neuropathy: A systematic review of 122 cases reported","volume":"261","author":"Petzold","year":"2014","journal-title":"J. Neurol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1136\/bjophthalmol-2016-309978","article-title":"Paediatric optic neuritis: Factors leading to unfavourable outcome and relapses","volume":"102","author":"Mizzi","year":"2018","journal-title":"Br. J. Ophthalmol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.joco.2019.03.005","article-title":"Update on Bartonella neuroretinitis","volume":"31","author":"Ksiaa","year":"2019","journal-title":"J. Curr. Ophthalmol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jns.2010.05.009","article-title":"Lyme optic neuritis","volume":"295","author":"Blanc","year":"2010","journal-title":"J. Neurol. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"60S","DOI":"10.1016\/S0002-9343(99)80045-X","article-title":"Ocular manifestations of Lyme disease","volume":"98","author":"Lesser","year":"1995","journal-title":"Am. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/pgmj.2004.020875","article-title":"Neurosyphilis with optic neuritis: An update","volume":"82","author":"Smith","year":"2006","journal-title":"Postgrad. Med. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.4103\/1673-5374.371400","article-title":"An overview on CV2\/CRMP5 antibody-associated paraneoplastic neurological syndromes","volume":"18","author":"Wang","year":"2023","journal-title":"Neural Regen. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jneuroim.2019.04.004","article-title":"Clinical characteristics of autoimmune GFAP astrocytopathy","volume":"332","author":"Kimura","year":"2019","journal-title":"J. Neuroimmunol."},{"key":"ref_21","first-page":"e653","article-title":"Glial Fibrillary Acidic Protein Autoimmunity: A French Cohort Study","volume":"98","author":"Ameli","year":"2022","journal-title":"Neurology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ana.24881","article-title":"Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: Analysis of 102 patients","volume":"81","author":"Flanagan","year":"2017","journal-title":"Ann. Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1055\/s-0037-1602382","article-title":"Ocular Involvement in Sarcoidosis","volume":"38","author":"Groen","year":"2017","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1136\/bjo.84.1.110","article-title":"Ocular involvement in sarcoidosis","volume":"84","author":"Rothova","year":"2000","journal-title":"Br. J. Ophthalmol."}],"container-title":["Neurology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2035-8377\/17\/3\/44\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:55:32Z","timestamp":1760028932000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2035-8377\/17\/3\/44"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["neurolint17030044"],"URL":"https:\/\/doi.org\/10.3390\/neurolint17030044","relation":{},"ISSN":["2035-8377"],"issn-type":[{"value":"2035-8377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,18]]}}}